Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

XFOR holding history

X4 Pharmaceuticals, Inc in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

XFOR overviewAll 13F holders of XFORFull Q2 2026 holdings

Shares (Q2 2026)
58,043
Value
$271.1K
% of portfolio
<0.1%
Quarters held
20
Since Q1 2021
Holdings of XFOR by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 202658,043$271.1K<0.1%−209,297−78.3%ReducedHolders
Q1 2026267,340$1.10M<0.1%+263,211+6,374.7%AddedHolders
Q4 20254,129$16.5K<0.1%−155,706−97.4%ReducedHolders
Q3 2025159,835$546.6K<0.1%+49,876+45.4%AddedHolders
Q2 2025109,959$208.9K<0.1%−57,947−34.5%ReducedConverted for a 1-for-30 splitHolders
Q1 20255,037,183$1.19M<0.1%+4,114,123+445.7%AddedHolders
Q4 2024923,060$677.5K<0.1%+661,934+253.5%AddedHolders
Q3 2024261,126$174.7K<0.1%+199,096+321.0%AddedHolders
Q2 202462,030$36.0K<0.1%−67,054−51.9%ReducedHolders
Q1 2024129,084$179.4K<0.1%+127,859+10,437.5%AddedHolders
Q4 20231,225$1.03K<0.1%−141,506−99.1%ReducedHolders
Q3 2023142,731$155.6K<0.1%+140,206+5,552.7%AddedHolders
Q2 20232,525$4.90K<0.1%−97,475−97.5%ReducedHolders
Q1 2023100,000$87.0K<0.1%+100,000NewHolders
Q4 20220$00.0%−9,525−100.0%Sold outHolders
Q3 20229,525$16.0K<0.1%+8,310+684.0%AddedHolders
Q2 20221,215$1.00K<0.1%−48−3.8%ReducedHolders
Q1 20221,263$2.00K<0.1%+595+89.1%AddedHolders
Q4 2021668$2.00K<0.1%+668NewHolders
Q3 20210$00.0%−122−100.0%Sold outHolders
Q2 2021122$1.00K<0.1%−3,868−96.9%ReducedHolders
Q1 20213,990$34.0K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.